Program
Recent Quotes
My Watchlist
Indicators
Local Stocks
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Achilles Therapeutics Plc (NQ: ACHL )

0.8150 +0.0150 (+1.87%)
Streaming Delayed Price Updated: 12:11 PM EDT, Jul 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Achilles Therapeutics Plc

Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines
From Achilles Therapeutics PLC
Via GlobeNewswire
Achilles Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
From Achilles Therapeutics PLC
Via GlobeNewswire
Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights
From Achilles Therapeutics PLC
Via GlobeNewswire
Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning
From Achilles Therapeutics PLC
Via GlobeNewswire
Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 Conference
From Achilles Therapeutics PLC
Via GlobeNewswire
Achilles Therapeutics Announces Publication of Nature Cancer ‘Comment’ on Strategy for Improved Neoantigen Immunogenicity Prediction
Newly developed computational tools and large datasets with low bias will lead to robust neoantigen prediction and improved personalized cancer therapies 
From Achilles Therapeutics PLC
Via GlobeNewswire
Achilles Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights
From Achilles Therapeutics PLC
Via GlobeNewswire
10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis
Via ACCESSWIRE
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation
Via Investor Brand Network
Exposures Product Safety
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation
EQNX::TICKER_START (NASDAQ:GNPX),(OTCQX:RHHBY),(NASDAQ:JAZZ),(NASDAQ:ALXO),(NASDAQ:ACHL) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures Product Safety
Achilles Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
From Achilles Therapeutics PLC
Via GlobeNewswire
Achilles Therapeutics to Present at Upcoming Conferences
From Achilles Therapeutics PLC
Via GlobeNewswire
Achilles Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights
From Achilles Therapeutics PLC
Via GlobeNewswire
Achilles Therapeutics’ New Immunogenicity Prediction Application of its AI-Powered PELEUS™ Platform Uniquely Identifies the Most Potent T Cell Antigens
- New AI module delivers a "Target-to-T cell” approach for revolutionizing the identification and prioritization of targets for personalized antigen approaches - 
From Achilles Therapeutics PLC
Via GlobeNewswire
Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
Achilles ADSs will continue to trade on the Nasdaq Global Select Market at this time, and the Company’s operations are not affected by the receipt of the Notice 
From Achilles Therapeutics PLC
Via GlobeNewswire
Achilles Therapeutics Announces Grant of US Patent Covering the Treatment of Patients with an Immunotherapy Targeting Neoantigens Based on Tumor HLA Status
From Achilles Therapeutics PLC
Via GlobeNewswire
Achilles Therapeutics to Present at Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
From Achilles Therapeutics PLC
Via GlobeNewswire
Achilles Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Business Highlights
From Achilles Therapeutics PLC
Via GlobeNewswire
Achilles Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Achilles Therapeutics PLC
Via GlobeNewswire
Achilles Therapeutics Presents Encouraging Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma at ESMO IO Congress 2022
From Achilles Therapeutics PLC
Via GlobeNewswire
Achilles Therapeutics to Present Early Proof of Concept of Safety and Clinical Activity of Clonal Neoantigen Reactive T Cells at the ESMO Immuno-Oncology Annual Congress 2022
From Achilles Therapeutics PLC
Via GlobeNewswire
Achilles Therapeutics Announces Grant of US Patent on Immunotherapies Targeting Clonal Neoantigens Identified Using Proprietary Method
- US patent is for an immunotherapy targeting clonal neoantigens identified by the Achilles Clonality Engine (ACE), including vaccine, antibody, and autologous T cell therapy approaches - 
From Achilles Therapeutics PLC
Via GlobeNewswire
Achilles Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights
From Achilles Therapeutics PLC
Via GlobeNewswire
Achilles Therapeutics Co-founder Professor Charles Swanton to Participate in Expert Roundtable Highlighting Pivotal Nature of Neoantigens as Targets in Cancer Cell Therapy
From Achilles Therapeutics PLC
Via GlobeNewswire
Secarna Pharmaceuticals and Achilles Therapeutics Sign Research, Option and License Agreement to Develop Optimized T Cell Therapies
- Secarna's LNAplusTM ASOs have the potential to optimize personalized T cell therapies being developed by Achilles - Secarna's industry-leading antisense oligonucleotide (ASO) platform LNAplusTM... 
From Secarna Pharmaceuticals GmbH & Co. KG
Via AccessWire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.